Chapter 015

Anti-Parkinson Drugs1

Vahn A. Lewis

CITED REFERENCES

  1. Albin RL, Mink JW: Recent advances in Tourette syndrome research. Trends Neurosci 29:175-182, 2006. PUBMED Abstract
  2. Alcaro A, Huber R, Panksepp J: Behavioral functions of the mesolimbic dopaminergic system: an affective neuroethological perspective. Brain Res Rev 56:283-321, 2007. PUBMED Abstract
  3. Aravamuthan BR, Muthusamy KA, Stein JF: Topography of cortical and subcortical connections of the human pedunculopontine and subthalamic nuclei. Neuroimage 37:694-705, 2007. PUBMED Abstract
  4. Barcia C, Bautista V, Sánchez-Bahillo A, et al: Changes in vascularization in substantia nigra pars compacta of monkeys rendered parkinsonian. J Neural Transm 112:1237-1248, 2005. PUBMED Abstract
  5. Barr J, Sharma CS, Sarkar S, et al: Nicotine induces oxidative stress and activates nuclear transcription factor kappa B in rat mesencephalic cells. Mol Cell Biochem 297:93-99, 2007. PUBMED Abstract
  6. Baumgärtner U, Buchholz HG, Bellosevich A, et al: High opiate receptor binding potential in the human lateral pain system. Neuroimage 30:692-699, 2006. PUBMED Abstract
  7. Belin AC, Westerlund M: Parkinson’s disease: a genetic perspective. FEBS J 275: 1377-1383, 2008. PUBMED Abstract
  8. Bodis-Wollner I: Neuropsychological and perceptual defects in Parkinson’s disease. Parkinsonism Relat Disord 9(Suppl 2):S83-S89, 2003. PUBMED Abstract
  9. Bogaerts VI, Theuns J, van Broeckhoven C: Genetic findings in Parkinson’s disease and translation into treatment: a leading role for mitochondria? Genes Brain Behav 7:129-151, 2007. PUBMED Abstract
  10. Braak H, Bohl JR, Muller CM, et al: Stanley Fahn Lecture 2005. The staging proceeding for inclusion body pathology associated with sporadic Parkinson’s disease reconsidered. Mov Disord 21:2042-2051, 2006. PUBMED Abstract
  11. Braak H, Sastre M, Bohl JR, et al: Parkinson’s disease: lesions in dorsal horn layer I, involvement of parasympathetic and sympathetic pre- and postganglionic neurons. Acta Neuropathol 113:421-429, 2007. PUBMED Abstract
  12. Cash R, Raisman R, Ploska A, et al: Dopamine D-1 receptor and cyclic AMP-dependent phosphorylation in Parkinson’s disease. J Neurochem 49:1075-1083, 1987. PUBMED Abstract
  13. Charles PD, Esper GJ, Davis TL: A definition of “on”: patient diaries compared to the UPDRS. Parkinsonism Relat Disord 5:99-101, 1999. PUBMED Abstract
  14. Chudler EH, Dong WK: The role of the basal ganglia in nociception and pain. Pain 60:3-38, 1995. PUBMED Abstract
  15. Corona T, Rivera C, Otero E, et al: A longitudinal study of the effects of an L-dopa drug holiday on the course of Parkinson’s disease. Clin Neuropharmacol 18:325-332, 1995. PUBMED Abstract
  16. Dagher A, Nagano-Saito A: Functional and anatomic magnetic resonance imaging in Parkinson’s disease. Mol Imaging Biol 9:234-242, 2007. PUBMED Abstract
  17. Dhariwala FA, Rajadhyaksha MS: An unusual member of the cdk family: cdk5. Cell Mol Neurobiol 28:351-369, 2008. PUBMED Abstract
  18. Doder M, Rabiner EA, Turjanski N, et al: Tremor in Parkinson’s disease and serotonergic dysfunction: an 11C-WAY 100635 PET study. Neurology 60:601-605, 2003. PUBMED Abstract
  19. Double KL, Rowe DB, Hayes M, et al: Identifying the pattern of olfactory deficits in Parkinson disease using the brief smell identification test. Arch Neurol 60:545-549, 2003. PUBMED Abstract
  20. Doya K: Complementary roles of basal ganglia and cerebellum in learning and motor control. Curr Opin Neurobiol 10:732-739, 2000. PUBMED Abstract
  21. Drucker-Colín R, Verdugo-Díaz L: Cell transplantation for Parkinson’s disease: present status. Cell Mol Neurobiol 24:301-316, 2004. PUBMED Abstract
  22. Elbaz A, Tranchant C: Epidemiologic studies of environmental exposures in Parkinson’s disease. Neurol Sci 262:37-44, 2007. PUBMED Abstract
  23. Fahn S; Parkinson Study Group: Does levodopa slow or hasten the rate of progression of Parkinson’s disease? J Neurol 252(Suppl 4):IV-37-IV-42, 2005. PUBMED Abstract
  24. Fornai F, Schlüter OM, Lenzi P, et al: Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein. Proc Natl Acad Sci U S A 102:3413-3418, 2005. PUBMED Abstract
  25. Friedlander AH, Mahler ME, Yagiela JA: Restless leg syndrome manifestations, treatment and dental implications. J Am Dent Assoc 137:755-761, 2006. PUBMED Abstract
  26. Fujita M, Imaizumi M, Zoghbi SS, et al: Kinetic analysis in healthy humans of a novel positron emission tomography radioligand to image the peripheral benzodiazepine receptor, a potential biomarker for inflammation. Neuroimage 40:43-52, 2008.
  27. Fukayo S, Nonaka N, Shimizu, T, et al: Oral health of patients with Parkinson’s disease: factors related to their better dental status. Tohoku J Exp Med 201:171-179, 2003. PUBMED Abstract
  28. Gasser T: Update on the genetics of Parkinson’s disease. Mov Disord 22(Suppl 17):S343-S350, 2007. PUBMED Abstract
  29. Gerhard A, Pavese N, Hotton G, et al: In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson’s disease. Neurobiol Dis 21:404-412, 2006. PUBMED Abstract
  30. Giladi N, McDermott MP, Fahn S, et al: Freezing of gait in PD: prospective assessment in the DATATOP cohort. Neurology 56:1712-1721, 2001. PUBMED Abstract
  31. Gilgun-Sherki Y, Melamed E, Ziv I, et al: Riluzole, an inhibitor of glutamatergic transmission, suppresses levodopa-induced rotations in 6-hydroxydopamine-lesioned rats. Pharmacol Toxicol 93:54-56, 2003.
  32. Goetz CG, Leurgans S, Raman R; Parkinson Study Group: Placebo-associated improvements in motor function: comparison of subjective and objective sections of the UPDRS in early Parkinson’s disease. Mov Disord 17:283-288, 2002.
  33. Goldman SM, Tanner CM, Oakes D, et al: Head injury and Parkinson’s disease risk in twins. Ann Neurol 60:65-72, 2006. PUBMED Abstract
  34. Goldman SM, Tanner CM, Olanow CW, et al: Occupation and parkinsonism in three movement disorders clinics. Neurology 65:1430-1435, 2005. PUBMED Abstract
  35. Gornemann T, Hubner H, Gmeiner P, et al: Characterization of the molecular fragment that is responsible for agonism of pergolide at serotonin 5-HT2B and 5-HT2A receptors. J Pharmacol Exp Ther 324:1136-1145, 2008. PUBMED Abstract
  36. Hanagasi HA, Ayribas D, Baysal K, et al: Mitochondrial complex I, II/III, and IV activities in familial and sporadic Parkinson’s disease. Int J Neurosci 115:479-493, 2005. PUBMED Abstract
  37. Hoshi E, Tremblay L, Féger P, et al: The cerebellum communicates with the basal ganglia. Nat Neurosci 8:1491-1493, 2005. PUBMED Abstract
  38. Hu G, Bidel S, Jousilahti P, et al: Coffee and tea consumption and the risk of Parkinson’s disease. Mov Disord 22:2242-2248, 2007. PUBMED Abstract
  39. Kawashima H, Iida Y, Kitamura Y, et al: Binding of 4-(4-chlorophenyl)-1-[4-(4-fluorophenyl)-4 oxobutyl]pyridinium ion (HPP+), a metabolite of haloperidol, to synthetic melanin: implications for the dopaminergic neurotoxicity of HPP+. Neurotoxicity Res 6:535-542, 2004. PUBMED Abstract
  40. Klivenyi P, Siwek D, Gardian G, et al: Mice lacking alpha-synuclein are resistant to mitochondrial toxins. Neurobiol Dis 21:541-548, 2006. PUBMED Abstract
  41. Laihinen A, Halsband U: PET imaging of the basal ganglia. J Physiol Paris 99:406-413, 2006. PUBMED Abstract
  42. Lewis MM, Slagle CG, Smith AB, et al: Task specific influences of Parkinson’s disease on the striato-thalamo-cortical and cerebello-thalamo-cortical motor circuitries. Neuroscience 147:224-235, 2007. PUBMED Abstract
  43. LeWitt PA: Clinical trials of neuroprotection for Parkinson’s disease. Neurology 63(7 Suppl 2):S23-S31, 2004. PUBMED Abstract
  44. Lobbezzo F, Naeije M: Dental implications of some common movement disorders: a concise review. Arch Oral Biol 52:395-398, 2007. PUBMED Abstract
  45. Marc RE, Jones BW, Anderson JR, et al: Neural reprogramming in retinal degeneration. Invest Ophthalmol Vis Sci 48:3364-3371, 2007. PUBMED Abstract
  46. Menon V, Levitin DJ: The rewards of music listening: response and physiological connectivity of the mesolimbic system. Neuroimage 28:175-184, 2005. PUBMED Abstract
  47. Middleton FA, Strick PL: Basal ganglia and cerebellar loops: motor and cognitive circuits. Brain Res Rev 31:236-250, 2000. PUBMED Abstract
  48. Monti JM, Monti D: The involvement of dopamine in the modulation of sleep and waking. Sleep Med Rev 11:113-133, 2007. PUBMED Abstract
  49. Newmark HL, Newmark J: Vitamin D and Parkinson’s disease—a hypothesis. Mov Disord 22:461-468, 2007. PUBMED Abstract
  50. Ogawa N: Factors affecting levodopa effects in Parkinson’s disease. Acta Med Okayama 54:95-101, 2000. PUBMED Abstract
  51. Ossowska K, Smialowska M, Kuter K, et al: Degeneration of dopaminergic mesocortical neurons and activation of compensatory processes induced by a long-term paraquat administration in rats: implications for Parkinson’s disease. Neuroscience 141:2155-2165, 2006. PUBMED Abstract
  52. Ouchi Y, Yoshikawa E, Sekine Y, et al: Microglial activation and dopamine terminal loss in early Parkinson’s disease. Ann Neurol 57:168-175, 2005. PUBMED Abstract
  53. Parkinson Study Group: Effects of tocopherol and deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med 328:176-183, 1993. PUBMED Abstract
  54. Postuma RB, Dagher A: Basal ganglia functional connectivity bases on a meta-analysis of 126 positron emission tomography and functional magnetic resonance imaging publications. Cerebral Cortex 16:1508-1521, 2006.
  55. Potenza MN, Voon V, Weintraub D: Drug Insight: impulse control disorders and dopamine therapies in Parkinson’s disease. Nat Clin Pract Neurol 3:664-672, 2007. PUBMED Abstract
  56. Rampello L, Alvano A, Battaglia G, et al: Tic disorders: from pathophysiology to treatment. Neurology 253:1-15, 2006. PUBMED Abstract
  57. Richard IH: Anxiety disorders in Parkinson’s disease. Adv Neurol 96:42-55, 2005. PUBMED Abstract
  58. Robertson LT, Hammerstad JP: Jaw movement dysfunction related to Parkinson’s disease and partially modified by levodopa. J Neurol Neurosurg Psychiatry 60:41-50, 1996. PUBMED Abstract
  59. Schestatsky P, Kumru H, Valls-Solé J, et al: Neurophysiologic study of central pain in patients with Parkinson disease. Neurology 69:2162-2169, 2007. PUBMED Abstract
  60. Scott DJ, Heitzeg MM, Koeppe RA, et al: Variations in the human pain stress experience mediated by ventral and dorsal basal ganglia dopamine activity. J Neurosci 26:10789-10795, 2006. PUBMED Abstract
  61. Schulze J, Toepfer M, Schroff KC, et al: Clindamycin and nicotinic neuromuscular transmission. Lancet 354:1792-1793, 1999. PUBMED Abstract
  62. Simon N, Gantcheva R, Bruguerolle B, et al: The effects of a normal protein diet on LevoDOPA plasma kinetics in advanced Parkinson’s disease more options. Parkinsonism Relat Disord 10:137-142, 2004. PUBMED Abstract
  63. Tafti M, Ghyselinck NB: Functional implication of the vitamin A signaling pathway in the brain. Arch Neurol 64:1706-1711, 2007. PUBMED Abstract
  64. Tanner CM, Goldman SM, Aston DA, et al: Smoking and Parkinson’s disease in twins. Neurology 58:581-588, 2002. PUBMED Abstract
  65. Taylor Tavares AL, Jefferis GS, Koop M, et al: Quantitative measurements of alternating finger tapping in Parkinson’s disease correlate with UPDRS motor disability and reveal the improvement in fine motor control from medication and deep brain stimulation. Mov Disord 20:1286-1298, 2005. PUBMED Abstract
  66. Tinazzi M, Del Vesco C, Fincati E, et al: Pain and motor complications in Parkinson’s disease. J Neurol Neurosurg Psychiatry 77:822-825, 2006. PUBMED Abstract
  67. Thobois S, Vingerhoets F, Fraix V, et al: Role of dopaminergic treatment in dopamine receptor down-regulation in advanced Parkinson disease—a positron emission tomographic study. Arch Neurol 61:1705-1709, 2004. PUBMED Abstract
  68. Weintraub D, Hurtig HI: Presentation and management of psychosis in Parkinson’s disease and dementia with Lewy bodies. Am J Psychiatry 164:1491-1498, 2007. PUBMED Abstract
  69. Youdim MB, Edmondson D, Tipton KF: The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci 7:295-309, 2006. PUBMED Abstract

GENERAL REFERENCES

  1. Adler CH, Ahlskog JE, editors: Parkinson’s disease and movement disorders: diagnosis and treatment guidelines for the practicing physician, Totowa, NJ, 2000, Humana Press.
  2. Alcaro A, Huber R, Panksepp J: Behavioral functions of the mesolimbic dopaminergic system: an affective neuroethological perspective, Brain Res Rev 56:283-321, 2007. PUBMED Abstract
  3. Alexander RE, Gage TW: Parkinson’s disease: an update for dentists, Gen Dent 48:572-582, 2000. PUBMED Abstract
  4. Allain H, Bentué-Ferrer D, Akwa Y: Disease-modifying drugs and Parkinson’s disease, Prog Neurobiol 84:25-39, 2008. PUBMED Abstract
  5. Cookson MR: The biochemistry of Parkinson’s disease. Annu Rev Biochem 74:29-52, 2005. PUBMED Abstract
  6. Cozzens J: Surgery for Parkinson’s disease, Dis Mon 53:227-242, 2007. PUBMED Abstract
  7. Davis KL, Martin E, Turko IV, et al: Novel effects of nitric oxide, Annu Rev Pharmacol Toxicol 41:203-236, 2001. PUBMED Abstract
  8. Huang Y, Cheung L, Rowe D: Genetic contributions to Parkinson’s disease, Brain Res Brain Res Rev 46:44-70, 2004. PUBMED Abstract
  9. Kaneko S, Hikida T, Watanabe D, et al: Synaptic integration mediated by striatal cholinergic interneurons in basal ganglia function, Science 289:633-637, 2000. PUBMED Abstract
  10. Tolosa E, Wenning G, Poewe W: The diagnosis of Parkinson’s disease, Lancet Neurol 5:75-86, 2006. PUBMED Abstract
  11. Wallace KB, Starkov AA: Mitochondrial targets of drug toxicity, Annu Rev Pharmacol Toxicol 40:353-388, 2000. PUBMED Abstract

1The author wishes to recognize Dr. Leslie Felpel for his past contributions to this chapter.